Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer
The complete response rate was similar for patients who received selumetinib and those who received radioactive iodine alone.
The complete response rate was similar for patients who received selumetinib and those who received radioactive iodine alone.
The multimodal AI platform proved more accurate than deep learning alone.
¹⁷⁷Lu-Dotatate improved the median overall survival by 11.7 months.
Patients with stage II or IV disease did not fare as well as patients with stage I or III disease.
There was no benefit to extending zoledronate treatment beyond 2 years.
The response rate was higher for patients with pancreatic NETs than for those with gastrointestinal NETs.
Data showed increases in endometrial cancer and obesity in women younger than 40.